LM-PCR Lentiviral Vector Integration Site Analysis

LM-PCR Lentiviral Vector Integration Site Analysis

1. Background

In the rapidly evolving landscape of gene therapy and cell therapy, lentiviral vectors have become indispensable tools for a broad range of therapeutic modalities—including CAR-T cell therapy—owing to their capacity to stably integrate exogenous genetic material into the host genome for long-term expression. As clinical applications continue to expand, regulatory scrutiny over integration safety has intensified accordingly. In late 2023, the U.S. Food and Drug Administration (FDA) issued its most stringent black box warning to date for all six approved CAR-T products on the market, alerting clinicians to the risk of T-cell malignancies in patients receiving BCMA- or CD19-directed autologous CAR-T cell immunotherapies—further underscoring the critical importance of integration safety assessment.[1]

China's National Medical Products Administration (NMPA) has, through a series of regulatory guidance documents, explicitly emphasized the necessity of evaluating the vector systems used in gene-modified cell therapies, including assessment of insertional mutagenesis and oncogenic/tumorigenic risks. Both the Non-Clinical Technical Guidelines for Gene-Modified Cell Therapy Products (Trial) issued in 2021 and the Guidelines for Pharmacological Research and Evaluation of Immune Cell Therapy Products (Trial) issued in 2022 clearly require that "integration sites and copy numbers be investigated using appropriate detection methods to explore their correlation with safety and efficacy."[2,3]

Conventional integration site detection methods—such as whole-genome sequencing (WGS) and LAM-PCR—are hindered by high false-positive rates, insufficient sensitivity, and other technical limitations in practical applications, making it difficult to meet increasingly stringent regulatory requirements. ZhuHai GeneRulor has developed and optimized a highly sensitive and precise integration site detection technology—LM-PCR—providing a reliable solution for the integration safety evaluation of CAR-T and other gene therapy products.

Table 1. Relevant Regulatory Guidance on Vector Integration Risk Assessment

2. Principle of LM-PCR

LM-PCR is a highly sensitive integration site detection method that achieves high-precision identification of vector–host genome junction sites through a ligation-mediated amplification strategy. The workflow begins with random fragmentation of genomic DNA by ultrasonication, followed by end repair and A-tailing. Double-stranded adapters bearing sequencing linkers are then ligated to both ends of the processed DNA fragments. Vector-specific primers are subsequently designed against the LTR sequence and paired with adapter primers; through two rounds of nested PCR, target fragments containing the vector–host junction are enriched. Finally, high-throughput sequencing combined with professional bioinformatic analysis enables precise determination of the chromosomal coordinates and functional features of each integration site.

ZhuHai GeneRulor designs customized two-round nested PCR specific primers based on the lentiviral vector LTR sequence provided by the client. This nested amplification strategy effectively enhances detection specificity and accurately captures virus–host genome junction regions. UMI (Unique Molecular Identifier) tagging is incorporated during library construction to eliminate PCR amplification bias, enabling accurate quantification of individual integration clones. Following sequencing, a professional bioinformatic pipeline performs comprehensive analysis and functional annotation of the integration sites, providing reliable data support for the safety assessment of vector integration.

Figure 1. Schematic Diagram of the LM-PCR Detection Workflow

3. Technical Innovations and Advantages of LM-PCR

3.1 Core Technical Innovations

3.1.1 Ultrasonic Fragmentation for Precise Library Construction

Ultrasonic shearing is employed to randomly fragment genomic DNA, achieving more uniform and controllable DNA fragmentation compared to enzymatic digestion methods:

Superior fragment size uniformity, avoiding the regional coverage bias caused by enzyme cutting site preferences;

Random shearing mode ensures that integration sites throughout the genome have an equal opportunity to be captured;

Fragment size distribution can be precisely controlled (typically 300–500 bp), optimizing downstream amplification efficiency;

Eliminates potential issues of incomplete digestion or variable enzyme activity associated with enzymatic approaches, enhancing library construction stability and reproducibility.

3.1.2 Nested PCR High-Specificity Amplification Strategy

A two-round nested PCR amplification strategy is applied, with both inner and outer primers designed against lentiviral LTR sequences and linker sequences:

First-round PCR: outer primers are used to initially enrich fragments containing vector–host junction sequences, reducing background interference;

Second-round PCR: inner primers are used to further specifically amplify target fragments, substantially improving the signal-to-noise ratio;

The two-round amplification strategy markedly reduces non-specific amplification products and minimizes false-positive rates;

Enhances detection sensitivity for low-abundance integration sites, ensuring that rare integration events are not missed.

3.1.3 UMI Molecular Barcoding for Precise Quantification

Double-stranded linkers carrying unique molecular identifiers (UMIs) are ligated to assign a unique molecular tag to each original DNA fragment, enabling precise tracking of original template molecules:

Effectively eliminates false-positive sites and quantitative bias introduced by PCR amplification preference;

Provides more accurate integration site frequency analysis, supporting clonality assessment;

Enables single-molecule-level integration event tracking, with a detection sensitivity of 0.001% (i.e., 1 integration event detectable in 100,000 cells).[4]

3.2 Method Validation and Performance Metrics

ZhuHai GeneRulor has conducted a comprehensive validation of LM-PCR technology in strict accordance with ICH Q2(R2)[5] and the FDA Guidance for Industry on Bioanalytical Method Validation.[6] Systematic validation results comparing WGS, nrLAM-PCR, liquid-phase hybrid capture, and LM-PCR demonstrate that LM-PCR performs optimally across all technical metrics:

Table 2. Method Validation Parameters and Results

4. Application Scenarios and Service Advantages

4.1 Application Scenarios

LM-PCR technology has broad applications in gene therapy product research, development, and regulatory processes:

CAR-T cell therapy safety assessment: precise detection of integration site distribution in CAR-T cells following lentiviral transduction, evaluation of insertional mutagenesis risk;

IND application support for gene therapy products: provision of integration site analysis and method validation reports compliant with regulatory requirements;

Integration-deficient lentivirus (IDLV) residual integration assessment: detection of low-frequency residual integration events from IDLV, comprehensive safety evaluation;

Cell line safety monitoring: quality control and batch-to-batch consistency assessment during cell production processes;

Clinical follow-up studies: support for long-term post-marketing safety monitoring and evaluation of gene therapy products.

4.2 Service Advantages

Technical leadership: ZhuHai GeneRulor's optimized LM-PCR technology overcomes the limitations of conventional methods, providing more accurate and comprehensive integration site analysis;

Certified quality management: the laboratory operates under an ISO 9001 quality management system and holds CNAS (China National Accreditation Service for Conformity Assessment) accreditation, ensuring data reliability and complete traceability;

Comprehensive method validation: full method validation encompassing sensitivity, specificity, accuracy, and precision has been completed; validation reports can directly support IND submissions;

Standardized reporting system: integration site analysis reports conforming to the latest CDE and FDA guidance requirements, fully supporting drug review and regulatory inspection;

Extensive track record: ZhuHai GeneRulor has assisted numerous pioneering companies in completing CAR-T product integration safety assessments and IND submission support, accumulating rich project experience and regulatory expertise.

5. LM-PCR Integration Site Analysis — Sample Report

ZhuHai GeneRulor provides comprehensive lentiviral integration site analysis reports that meet regulatory requirements, including detailed sequencing data quality assessment, per-sample sequencing depth statistics, reference genome alignment analysis, and integration site count statistics as foundational information. In addition, the report includes the following core content:

(1) Lentiviral Vector Overall Integration Ratio Statistics: Statistics of the proportion of integrated LTR reads relative to total reads are calculated and reported.

Figure 2. Lentiviral Vector Overall Integration Ratio Statistics (Example)

(2) Integration Site Quantitative Statistics: Statistical analysis is performed on all integration sites within the sample. For each library, detected integration sites are filtered by retaining only sites supported by a UMI count ≥ 5, followed by clustering of adjacent sites within ≤ 500 bp of each other.

Figure 3. Integration Site Quantitative Statistics (Example)

(3) Integration Site UMI Support Count and Integration Frequency Statistics: The UMI count and integration frequency detected at each integration site are individually calculated, and integration sites are ranked in descending order by UMI count to present integration site information. Integration frequency is calculated as: integration site UMI count / total UMI count of filtered integration sites.

Figure 4. Integration Site Integration Frequency Statistics (Example)

Figure 5. Integration Site Circos Complement Plot (Example)

(4) Integration Site Genomic Annotation and Oncogenic Risk Assessment: Comprehensive genomic functional annotation is performed for all detected integration sites, analyzing the distribution of integration sites across genomic functional elements (exons, introns, promoters, UTRs, etc.). ONCOGENE and TSG (tumor suppressor gene) databases are additionally utilized for professional annotation of integration sites, systematically evaluating the potential oncogenic risk that exogenous sequence integration may pose to host genes, and providing a genome-wide integration site distribution pattern analysis.

Figure 6. Integration Site Genomic Annotation and Oncogenic Risk Assessment (Example)

(5) Sample Clonal Dominance Statistics: Evaluation of whether dominant integration sites (clonal dominance) exist within the sample.

Figure 7. Integration Site Genomic Annotation and Oncogenic Risk Assessment (Example)

(6) Oncogene Annotation: Integration sites associated with proto-oncogenes and tumor suppressor genes are specifically highlighted and labeled, with safety risk assessment performed.

Figure 8. Sample Clonal Dominance Statistics (Example)

(7) Gene Functional Analysis: GO and KEGG pathway enrichment analysis is performed on genes harboring integration events, to assess potential biological impacts.

Figure 9. GO and KEGG Pathway Enrichment Analysis (Example)

6. LM-PCR Integration Site Detection Service Contents

Table 3. Service Workflow and Contents

*Standard service turnaround: 25–30 business days

7. Sample Requirements

*Notes: ① All samples must comply with the above standards to ensure the accuracy and reliability of detection results; ② Clients may also submit fresh cell samples for DNA extraction, with a cell requirement of > 2×10⁷ cells per site; ③ For special sample types, please contact ZhuHai GeneRulor's technical team in advance (Tel: 400-6309596; Product Orders/Technical Support: service@generulor.com).

8. References

[1] FDA. (2024). FDA requires warnings about secondary malignancies for BCMA-directed and CD19-directed autologous CAR T cell immunotherapies.

[2] National Medical Products Administration. (2021). Non-Clinical Technical Guidelines for Gene-Modified Cell Therapy Products (Trial).

[3] National Medical Products Administration. (2022). Technical Guidelines for Pharmacological Research and Evaluation of Immune Cell Therapy Products (Trial).

[4] Yin J, et al. (2019). Optimizing genome editing strategy by primer-extension-mediated sequencing. Cell Discovery, 5, 18.

[5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised Guideline: Validation of Analytical Procedures Q2(R2). ICH, November 2023.

[6] U.S. Food and Drug Administration. (2018). Bioanalytical Method Validation: Guidance for Industry. U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research and Center for Veterinary Medicine.

[7] Corre, G., et al. (2023). Evaluation of diversity indices to estimate clonal dominance in gene therapy studies. Molecular Therapy Methods & Clinical Development, 29, 418–425.